News and Announcements
Meet the sponsors of the CREATE Series: a shared vision delivering value
- Published August 14, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
As our CREATE series quickly approaches, we at Wholesale Investor are happy to introduce our sponsors for the event. It’s our vision to introduce promising companies to important investors, however this would not be possible without the backing of our partners. We’ve teamed up with S&P Capital IQ and Ansarada to create more opportunities to facilitate more investments through our platform.
S&P Capital IQ
S&P Capital IQ is a platform for financial professionals that combines global financial intelligence with tools for analysis, ideation, and efficiency. The company is ideal for industry research due to its over 5,000 financial and 3,000 qualitative data points available for screening on 17 industries.
S&P Capital IQ’s keynote speaker will be Andrew Melville, the Director of Investment Banking and Private Equity. He will discuss their expert insight into the current market in terms of the increase of funds operating in the alternative asses space, and how they are providing increased value in the emerging companies space. S&P Capital IQ is also working on creating a brand new platform that will focus on the new trends in funds working in the alternative asset space.
Ansarada
Ansarada Data Rooms simplify event execution through the combination of artificial intelligence and machine learning. The company allows for a powerful way to run your transactions with artificial intelligence driven insights and security. These data rooms essentially make investors lives much easier. You can explore more about Ansarada’s performance on their website.
Early-bird ticket sales end soon, there are only 50 of these tickets left! If you are interested in attending CREATE Sydney, please register below.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
